Taniguchi K, Hoshino Y, Nishikawa K, Green K Y, Maloy W L, Morita Y, Urasawa S, Kapikian A Z, Chanock R M, Gorziglia M
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.
J Virol. 1988 Jun;62(6):1870-4. doi: 10.1128/JVI.62.6.1870-1874.1988.
The neutralization epitopes of human and simian rotavirus protein VP7 were studied by producing six neutralizing monoclonal antibodies (N-MAbs) and using these N-MAbs to select antigenic mutants that resisted neutralization by the N-MAbs used for their selection. Cross-neutralization tests between the N-MAbs and the antibody-selected antigenic mutants identified one cross-reactive and five distinct serotype-specific neutralization epitopes which operationally overlapped one another and constituted a single antigenic site. In addition, the amino acid substitutions in human rotavirus VP7 that are responsible for the antigenic alterations in the mutants selected with anti-VP7 cross-reactive or serotype-specific N-MAbs were identified. All the amino acid substitutions in the antigenic mutants occurred in one of two variable regions: amino acids 87 to 101 and 208 to 221.
通过制备六种中和单克隆抗体(N-MAbs)并使用这些N-MAbs筛选出能抵抗用于筛选它们的N-MAbs中和作用的抗原突变体,对人和猿猴轮状病毒蛋白VP7的中和表位进行了研究。N-MAbs与抗体筛选的抗原突变体之间的交叉中和试验确定了一个交叉反应性中和表位和五个不同的血清型特异性中和表位,这些表位在功能上相互重叠,构成一个单一的抗原位点。此外,还确定了人轮状病毒VP7中导致用抗VP7交叉反应性或血清型特异性N-MAbs筛选的突变体发生抗原改变的氨基酸替换。抗原突变体中的所有氨基酸替换均发生在两个可变区之一:氨基酸87至101和208至221。